|
Related Articles |
Parental perceived benefits of OROS-methylphenidate treatment for the child with attention-deficit/hyperactivity disorder and for parents themselves.
Pharmacopsychiatry. 2013 Jun;46(4):137-46
Authors: Kim JW, Park S, Kim BN, Shin MS, Cho SC, Kim JH, Son JW, Shin YM, Chung US, Han DH
Abstract
Given the shortage of studies on parental perceived benefits of OROS-methylphenidate treatment in Asian populations, we assessed parental response to OROS-methylphenidate treatment of Korean children with attention-deficit/hyperactivity disorder (ADHD), in relation to children’s academic performance and behavioral symptoms as well as parental rearing stress and depressive symptoms.We enrolled 132 medication-naïve children with ADHD into a multicenter, open-label, 12-week trial of OROS-MPH. The outcome measures were the ADHD rating scale-IV (ADHD-RS), the comprehensive attention test and academic performance rating scale, and the clinical global impression (CGI)-severity/improvement instrument (for the children) and Beck depression inventory and parenting stress index (for their parents).We found parent-perceived improvements in children’s ADHD-related behavioral symptoms and academic function and their parents’ depressive symptoms and parenting stress. Investigator-rated ADHD symptoms and subjects’ neuropsychological function were also improved (p<0.001).Parents of Korean children with ADHD perceive that OROS-methylphenidate treatment improves their children’s academic function and behavior as well as their own child-rearing stress and emotional state. These findings must be interpreted with caution, due to a non-comparative open-label trial.
PMID: 23364873 [PubMed – indexed for MEDLINE]

